Showing 5291-5300 of 5689 results for "".
- Eyepromise Introduces Screen Shield Pro All-Natural Eye Vitamin for Screen Time Protection for Adultshttps://modernod.com/news/eyepromise-introduces-screen-shield-pro-all-natural-eye-vitamin-for-screen-time-protection-for-adults/2476661/EyePromise announced the introduction of Screen Shield Pro to its premium eye vitamin line. EyePromise’s Screen Shield Pro is designed to protect and relieve the associated symptoms of digital eye strain of adults (ages 18 and up) who spend 8+ hours staring at digital screens while working, gami
- Ribomic Announces Positive Topline Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-positive-topline-results-from-the-phase-1-2a-clinical-trial-of-rbm-007-sushi-study-in-subjects-with-wet-amd/2476656/Ribomic announced positive topline results from its SUSHI study, a phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet age-related macular degeneration (AMD). The SUSHI study achiev
- Pre-Pilot Clinical Trial from Ocutrx Vision Technologies Yields Exciting Results for Patients with AMDhttps://modernod.com/news/pre-patient-trial-from-ocutrx-vision-technologies-yields-exciting-results-for-patients-with-amd/2476659/Ocutrx Vision Technologies announced the results of the first pre-pilot clinical trial for the company’s Oculenz AR glasses. In the single arm crossover study of subjects with advanced macular degeneration, the Oculenz AR glasses significantly improved the ability of subjects to read small letter
- Glaucoma Drugs Continue to Battle for Market Sharehttps://modernod.com/news/glaucoma-drugs-continue-to-battle-for-market-share/2476655/Two new glaucoma drugs introduced in the US in 2018 continue to battle for market share. Rhopressa, from Aerie Pharmaceuticals, got out of the gate faster than Vyzulta from Bausch Health. The growth rate for both drugs slowed in the first quarter of 2019, which is normal after a product launch, a
- Amarantus Announces Issuance of US Patent Covering MANF Treatment of Wolfram’s Syndrome, Retinitis Pigmentosa, and Glaucomahttps://modernod.com/news/amarantus-announces-issuance-of-us-patent-covering-manf-treatment-of-wolframs-syndrome-retinitis-pigmentosa-and-glaucoma/2476653/Amarantus Bioscience Holdings announced that subsidiary MANF Therapeutics was issued US Patent No. 10,195,251 entitled “Methods of Treatment for Retinal Diseases Using MANF and CDNF” that covers the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) or cerebral dopamine
- Brits in the Dark Over Eye Health According to Orbis UKhttps://modernod.com/news/brits-in-the-dark-over-eye-health-according-to-orbis-uk/2476651/New research reveals that over half of Brits (53%) do not get their eyes tested every 2 years as recommended, and just over 1 in 10 (11%) can’t remember the last time they went to the optician. This is despite 45% of those surveyed listing sight as their most valuable sense. The surv
- Post-Approval Study Finds No Surprises With Argus II Retinal Implanthttps://modernod.com/news/post-approval-study-finds-no-surprises-with-argus-ii-retinal-implant/2476647/Post-approval follow-up of the Argus II Retinal Prosthesis System shows safety and visual function outcomes similar to those in previous trials, according to a company-funded study, as reported in Reuters. With a CE mark granted in 2011, the device became the first retinal prosthesis to b
- Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucomahttps://modernod.com/news/aerpio-initiates-phase-1b-clinical-trial-of-topical-ocular-formulation-of-akb-9778-for-primary-open-angle-glaucoma/2476645/Aerpio Pharmaceuticals dosing of the first subject in a phase 1b trial of a topical ocular formulation of AKB-9778 in development for treatment of primary open angle glaucoma (POAG). The phase 1 study is a double-masked, multiple-ascending dose trial and will enroll four cohorts of 12 subj
- OcuSoft Introduces NEW OcuSoft Lid Scrub Allergy Eyelid Treatment for Red, Itchy Allergy Eyeshttps://modernod.com/news/ocusoft-introduces-new-ocusoft-lid-scrub-allergy-eyelid-treatment-for-red-itchy-allergy-eyes/2476646/OcuSoft announced the availability of new OcuSoft Lid Scrub Allergy Eyelid Cleanser for allergy conditions in convenient pre-moistened pads. OcuSoft Lid Scrub Allergy removes oil, debris, pollen and other contaminants from the eyelids while utilizing Green Tea Extract, Tea Tree Oil and PSG
- Our Tears Could One Day Tell Us If We Have Glaucomahttps://modernod.com/news/our-tears-could-one-day-tell-us-if-we-have-glaucoma/2476643/Contrary to what many think, high pressure inside the eye does not define glaucoma and investigators want to know if the proteins circulating in the fluid of our eyes might, according to researchers at the Medical College of Georgia at Augusta University. While some patients do have classi